Generate Biomedicines Q3 Loss Narrows, Revenue Falls
08:01 AM EST, 11/12/2026 (MT Newswires) -- Generate Biomedicines (GENB) reported Q3 net loss of $0.6
Related stories
Maire Expects LNG Licensing Business to Generate at Least $25 Million EBITDA in 2027
Maire expects its acquired LNG licensing business to generate at least USD 25 million in EBITDA in 2027.
M impact | EARNINGS | Nov 15, 2026, 06:58 PM UTC
StubHub Raises Full-Year Gross Merchandise Sales Outlook to $10.3 Billion
StubHub raised its full-year gross merchandise sales outlook to $10.3 billion from $10.1 billion.
M impact | EARNINGS | Nov 15, 2026, 02:03 AM UTC
Merlin Properties Raises 2026 FFO Guidance to EUR 0.58 per Share
Merlin Properties raised its 2026 FFO guidance to EUR 0.58 per share and updated its strategy for its 704 MW data center portfolio.
M impact | EARNINGS | Nov 14, 2026, 08:03 PM UTC
Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million
Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million Lucara Diamond raised
L impact | EARNINGS | Nov 14, 2026, 01:10 AM UTC
Gilead Expects HIV Revenue to Grow About 12% in 2026
Gilead expects HIV revenue to grow about 12% in fiscal 2026.
M impact | EARNINGS | Nov 14, 2026, 12:44 AM UTC
Asante Gold Withdraws 2026 Production and Cost Guidance
Asante withdrew its 2026 guidance for 275,000–300,000 equivalent ounces at consolidated AISC of $3,200–$3,600/oz after Bibiani underperformed. Nine-month production was 165,594 equ
M impact | EARNINGS | Nov 13, 2026, 11:27 PM UTC